Zevra Q2 2020 Earnings Report
Key Takeaways
KemPharm reported revenue of $6.9 million, driven by a $5.0 million milestone payment and $1.9 million from research and development services. Net income for the quarter was $0.9 million, or $0.01 per share, compared to a net loss of $9.3 million for the same period in 2019. Cash and cash equivalents increased by $4.0 million to $6.6 million as of June 30, 2020.
FDA accepted the New Drug Application (NDA) for KP415.
Received the $5 million milestone payment upon FDA’s acceptance of the KP415 NDA.
Corium, Inc. will lead all commercialization activities for KP415.
Two U.S. patents governing KP415 and KP484 were issued with an expiration date of December 9, 2037.
Zevra
Zevra
Forward Guidance
Based on the Company’s current operating forecast, the Company believes that its expected revenues and existing resources are sufficient to continue operations past the potential March 2, 2021 PDUFA date for the KP415 NDA and up to the debt maturity date of March 31, 2021.